Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Aurora Cannabis is a Canadian licensed producer operating cultivation facilities in Alberta (Aurora Sky, Aurora River) and Ontario, producing medical and adult-use cannabis for domestic and international markets. The company has undergone significant restructuring since 2020, divesting non-core assets and reducing cultivation capacity to focus on profitability over scale. With a $200M market cap and 27% revenue growth, Aurora is transitioning from a distressed turnaround story to a smaller, cash-generative operator in a maturing Canadian cannabis market facing pricing pressure and regulatory constraints.
Aurora generates revenue by cultivating cannabis at indoor facilities (Aurora Sky's 800,000 sq ft facility in Alberta, Aurora River in Ontario) and selling finished products through provincial wholesale channels (adult-use) or direct to patients (medical). Gross margins of 54.6% reflect improved cultivation efficiency post-restructuring, though pricing remains under pressure from oversupply in Canadian market. Operating leverage comes from fixed facility costs - higher utilization drives margin expansion. Company competes on brand recognition (Aurora, San Rafael '71, Daily Special value brand), product innovation (vapes, edibles), and cost position. Limited pricing power due to commoditization of dried flower, but premium brands and medical channel provide some differentiation.
Canadian cannabis market pricing trends - wholesale price per gram for dried flower, which has declined 40%+ since 2020 peak
Regulatory developments - US federal rescheduling/legalization speculation, Canadian regulatory changes on retail store caps, product formats
Quarterly revenue growth and path to sustained profitability - investors focus on whether Aurora can maintain positive net income after 102% growth
Market share trends in key provinces - Ontario, Alberta, Quebec adult-use sales data released monthly
International expansion progress - German medical market growth, EU export volumes, though currently small revenue contributor
Canadian market oversupply and pricing pressure - licensed cultivation capacity far exceeds demand, driving wholesale prices down 40%+ since 2020 with limited floor in sight
Regulatory uncertainty on US federal legalization - potential Schedule III rescheduling or state-level expansion could attract large CPG/pharma entrants with superior capital and distribution, though cross-border trade barriers remain
Commoditization of dried flower - 60%+ of market remains undifferentiated flower products with minimal brand loyalty, limiting pricing power
Provincial retail constraints - some provinces cap store licenses, limiting distribution channel growth
Competition from larger Canadian LPs - Canopy Growth (CGC), Tilray, Cronos have stronger balance sheets and brand portfolios
Illicit market competition - illegal dispensaries and online sellers offer lower prices without tax burden, capturing estimated 30-40% of total consumption
Private label and value brands from provincial distributors - government entities launching own brands at aggressive price points
MSO entry risk if US-Canada trade barriers fall - US multi-state operators like Curaleaf, Trulieve have larger scale and operational expertise
Negative free cash flow of -$0.0B with minimal cash generation - company may need additional capital raises, diluting shareholders
Limited access to traditional debt markets due to cannabis legal status - forces reliance on dilutive equity or expensive alternative financing
Asset impairment risk - Aurora has written down billions in goodwill/assets since 2019; remaining $400M in assets (P/B of 0.5x) could face further impairments if market deteriorates
Working capital management - current ratio of 3.06 is healthy but inventory obsolescence risk exists in fast-moving consumer goods with shelf life
moderate - Cannabis shows some defensive characteristics as a consumer staple with habitual use patterns, but adult-use discretionary spending is sensitive to consumer confidence and disposable income. Medical cannabis is more recession-resistant. Canadian market maturity (5+ years post-legalization) means growth is tied to market share gains rather than category expansion. Economic weakness could pressure value-brand sales volumes while premium products face trading down.
Rising rates negatively impact Aurora through higher cost of capital for a cash-burning business with limited access to traditional financing (cannabis remains federally illegal in US, limiting banking relationships). Higher rates also compress valuation multiples for unprofitable/low-margin growth stocks. However, Aurora's low debt/equity of 0.19 limits direct interest expense impact. Rate cuts would be positive for equity valuation and potential M&A activity in sector.
Minimal direct credit exposure as Aurora operates B2C and sells to provincial distributors (government entities in most provinces, low credit risk). However, the company's own access to credit markets is constrained by cannabis's legal status, making equity dilution the primary capital source historically. Tight credit conditions limit acquisition financing and working capital flexibility.
speculative growth/momentum - Aurora attracts retail investors betting on US legalization catalyst, turnaround story believers, and sector rotation traders. The 40% one-year decline and low market cap indicate this is a high-risk, high-volatility name. Not suitable for value investors (despite 0.5x P/B) due to asset quality concerns and uncertain earnings power. No dividend, negative FCF, and 102% net income growth from low base make this a binary bet on sector recovery rather than fundamental value.
high - Cannabis stocks exhibit 2-3x market volatility driven by regulatory headline risk, sector sentiment swings, and low institutional ownership. Aurora's small market cap ($200M) amplifies volatility. Stock down 40% in past year reflects sector-wide derating as US legalization timeline extends and Canadian market disappoints. Options market likely prices high implied volatility around earnings and regulatory events.